Pfizer delivered stronger-than-expected second-quarter results, underscoring the benefits of cost-cutting and steady demand for its top-selling medicines. Revenue rose 10% from a year earlier to $14.65 billion, outpacing the $13.5 billion analysts projected, while adjusted earnings climbed to $0.78 a share, well above the $0.58 consensus. Reported net income was $2.91 billion, equivalent to $0.51 a share. On the back of the beat, the New York-based drugmaker lifted its full-year adjusted earnings outlook to $2.90–$3.10 a share, up from $2.80–$3.00, even after absorbing an estimated $0.20 one-time impact tied to its 3SBio transaction. Pfizer kept its 2025 revenue forecast unchanged at $61 billion to $64 billion. Management reiterated that the company remains on track to generate about $7.2 billion in cumulative net cost savings by the end of 2027, supporting margin expansion as it advances late-stage pipeline assets. The guidance increase signals confidence that the efficiency programme and stable product portfolio can offset lingering volatility in pandemic-related sales.